three
antihiv
drug
ritonavir
lopinavir
darunavir
might
therapeut
effect
coronaviru
diseas
studi
structur
model
two
sever
acut
respiratori
syndrom
coronaviru
proteas
coronaviru
endopeptidas
papain
like
viral
proteas
plvp
built
homolog
model
ritonavir
lopinavir
darunavir
dock
model
respect
follow
energi
minim
proteasedrug
complex
simul
ritonavir
bind
suitabl
induc
signific
conform
chang
lopinavir
also
bind
suitabl
induc
signific
conform
chang
darunavir
bind
plvp
suitabl
slight
conform
chang
plvp
suggest
therapeut
effect
ritonavir
lopinavir
may
mainli
due
inhibitori
effect
ritonavir
may
stronger
efficaci
inhibitori
effect
darunavir
potenti
therapeut
effect
may
mainli
due
inhibitori
effect
plvp
authorfund
right
reserv
reus
allow
without
permiss
decemb
coronaviru
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
occur
wuhan
china
quickli
becam
rise
global
concern
sinc
world
health
organ
declar
sixth
public
health
emerg
intern
concern
pheic
januari
time
februari
case
confirm
china
patient
die
result
mortal
novel
speci
nonseg
positivesens
rna
viru
spread
distribut
human
mammal
previou
studi
discov
belong
distinct
clade
associ
human
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
shi
zl
et
al
found
share
sequenc
ident
sarsrel
coronaviru
ident
wholegenom
level
bat
coronaviru
correspond
origin
may
wild
anim
sold
huanan
seafood
wholesal
market
recent
clinic
research
found
dyspnea
might
occur
fifth
day
acut
respiratori
distress
syndrom
eighth
day
first
symptom
median
organ
dysfunct
death
also
occur
sever
case
howev
still
specif
treatment
find
drug
fight
top
prioriti
trial
fifth
edit
diagnosi
treatment
guidelin
issu
nation
health
commiss
peopl
republ
china
http
wwwnhcgovcn
recommend
use
kaletra
treatment
kaletra
antihiv
drug
compos
two
proteas
inhibitor
ritonavir
ca
lopinavir
ca
might
therapeut
effect
coronaviru
diseas
like
sar
mer
howev
whether
inhibit
treat
lack
clinic
evid
random
clinic
trial
safeti
use
patient
unclear
otherwis
lanjuan
li
infecti
diseas
scientist
academician
chines
academi
engin
recommend
darunavir
ca
also
hiv
proteas
inhibitor
treatment
although
inhibitori
effect
darunavir
verifi
vitro
therapeut
effect
still
unknown
time
mechan
drug
inhibit
also
unknown
coronavirus
includ
synthes
polyprotein
follow
hydrolyz
produc
structur
function
protein
suggest
ritonavir
lopinavir
darunavir
may
block
multipl
cycl
inhibit
proteas
preliminarili
understand
inhibitori
effect
drug
studi
molecular
model
proteas
built
homolog
model
follow
dock
drug
proteas
respect
addit
dynam
interact
drug
proteas
also
simul
evalu
bind
effect
drug
proteas
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
sinc
gene
proteas
identifi
ten
gene
directli
proteaselik
conserv
domain
polyprotein
genbank
viru
analyz
ncbi
conserv
domain
search
servic
http
wwwncbinlmnihgovstructurecddwrpsbcgi
sequenc
found
proteaselik
domain
use
build
molecular
model
homolog
model
swissmodel
http
swissmodelexpasyorg
evalu
qualiti
verifi
score
errat
score
prove
score
ramachandran
plot
built
model
automat
creat
structur
analysi
verif
server
version
http
servicesnmbiuclaedusav
dock
ritonavir
lopinavir
darunavir
proteas
respect
discoveri
studio
softwar
version
accelri
softwar
inc
use
dock
one
proteas
would
set
receptor
possibl
dock
site
would
found
sphere
whose
radiu
unit
would
set
optim
dock
site
follow
semiflex
dock
unproton
ritonavir
lopinavir
darunavir
receptor
proteas
dock
ligand
libdock
modul
discoveri
studio
softwar
respect
preliminari
dock
result
would
evalu
libdock
score
intermolecular
interact
discoveri
studio
softwar
analyz
structur
chang
proteas
caus
inducedfit
effect
bind
drug
steepest
descent
conjug
gradient
algorithm
use
minim
energi
proteasedrug
complex
success
minim
modul
discoveri
studio
softwar
calcul
fix
constraint
backbon
protein
use
first
remov
later
search
conserv
domain
sequenc
polyprotein
two
proteaselik
domain
found
one
domain
coronaviru
endopeptidas
locat
polyprotein
sequenc
domain
papain
like
viral
proteas
plvp
locat
sequenc
sequenc
plvp
directli
use
subsequ
homolog
model
residu
ctermin
sequenc
delet
subsequ
homolog
model
minim
disord
structur
model
model
built
accord
automat
found
templat
toprat
model
model
homodim
ligand
select
repres
structur
model
plvp
model
built
accord
automat
found
templat
toprat
model
model
monom
zinc
ion
ligand
select
repres
structur
plvp
structur
two
select
model
avail
supplement
file
detail
inform
evalu
score
ramachandran
plot
two
model
shown
figur
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
optim
dock
site
pocket
two
subunit
dock
drug
site
pose
found
dock
ritonavir
libdock
score
optim
pose
pose
found
dock
lopinavir
libdock
score
optim
pose
pose
found
dock
darunavir
libdock
score
optim
pose
optim
dock
site
plvp
pocket
one
side
protein
dock
drug
site
pose
found
dock
ritonavir
libdock
score
optim
pose
pose
found
dock
lopinavir
libdock
score
optim
pose
pose
found
dock
darunavir
libdock
score
optim
pose
interact
proteas
drug
optim
pose
shown
figur
structur
dock
proteasedrug
complex
optim
pose
energi
minim
avail
supplement
file
energi
minim
proteasedrug
complex
structur
chang
differ
energi
minim
proteasedrug
complex
shown
figur
structur
proteasedrug
complex
energi
minim
avail
supplement
file
studi
two
model
two
proteaselik
domain
plvp
polyprotein
built
sinc
two
model
built
take
highli
homolog
crystal
structur
templat
qualiti
quit
consider
difficult
obtain
crystal
structur
plvp
short
time
great
signific
use
reliabl
structur
model
predict
dynam
interact
molecul
ritonavir
lopinavir
two
drug
seem
suitabl
bind
rather
plvp
energi
minim
suggest
dock
ritonavir
lopinavir
induc
chang
conform
significantli
bind
drug
tightli
moreov
ritonavir
suitabl
lopinavir
bind
shown
figur
interact
ritonavir
bind
tighter
contrari
neither
ritonavir
lopinavir
seem
suitabl
bind
plvp
sinc
bind
becom
less
tight
energi
minim
darunavir
drug
seem
suitabl
bind
plvp
rather
energi
minim
suggest
dock
plvp
darunavir
chang
conform
significantli
fit
plvp
whose
conform
also
induc
slightli
chang
contrari
darunavir
seem
suitabl
bind
sinc
bind
darunavir
becom
less
tight
energi
minim
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
sinc
catalyt
mechan
plvp
domain
unknown
unabl
determin
whether
ritonavir
lopinavir
darunavir
competit
noncompetit
inhibitor
although
drug
peptid
analogu
seem
competit
bind
ritonavir
lopinavir
might
lead
signific
conform
chang
conclus
whether
ritonavir
lopinavir
competit
noncompetit
sinc
competit
noncompetit
inhibitor
may
significantli
chang
conform
receptor
darunavir
bind
plvp
suitabl
chang
conform
slight
conform
chang
plvp
like
competit
inhibitor
plvp
conclus
therapeut
effect
ritonavir
lopinavir
coronaviru
diseas
may
mainli
due
inhibitori
effect
ritonavir
may
stronger
efficaci
inhibitori
effect
darunavir
potenti
therapeut
effect
may
mainli
due
inhibitori
effect
plvp
howev
still
limit
studi
catalyt
mechan
plvp
still
unknown
studi
still
focus
figur
mechan
ritonavir
lopinavir
darunavir
block
procedur
safeti
actual
effect
drug
human
bodi
also
carri
verifi
random
clinic
control
studi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
supplement
file
structur
model
supplement
file
structur
model
plvp
supplement
file
structur
dock
complex
optim
pose
energi
minim
supplement
file
structur
dock
complex
optim
pose
energi
minim
supplement
file
structur
dock
complex
optim
pose
energi
minim
supplement
file
structur
dock
plvpritonavir
complex
optim
pose
energi
minim
supplement
file
structur
dock
plvplopinavir
complex
optim
pose
energi
minim
supplement
file
structur
dock
plvpdarunavir
complex
optim
pose
energi
minim
supplement
file
structur
dock
complex
energi
minim
supplement
file
structur
dock
complex
energi
minim
supplement
file
structur
dock
complex
energi
minim
supplement
file
structur
dock
plvpritonavir
complex
energi
minim
supplement
file
structur
dock
plvplopinavir
complex
energi
minim
supplement
file
structur
dock
plvpdarunavir
complex
energi
minim
conflict
interest
declar
structur
model
homodim
ligand
built
take
pdb
templat
chain
model
consist
amino
acid
residu
sequenc
ident
templat
structur
model
plvp
monom
zinc
ion
ligand
built
take
pdb
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
templat
model
plvp
consist
amino
acid
residu
sequenc
ident
templat
evalu
score
ramachandran
plot
two
model
automat
creat
structur
analysi
verif
server
version
http
servicesnmbiuclaedusav
three
score
use
evalu
model
verifi
score
errat
score
prove
score
higher
verifi
score
errat
score
well
lower
prove
score
reason
model
built
structur
complex
energi
minim
complex
energi
minim
complex
energi
minim
complex
energi
minim
complex
energi
minim
complex
energi
minim
plvpritonavir
complex
energi
minim
plvpritonavir
complex
energi
minim
plvplopinavir
complex
energi
minim
plvplopinavir
complex
energi
minim
plvpdarunavir
complex
energi
minim
plvpdarunavir
complex
energi
minim
chain
shown
white
chain
b
shown
yellow
main
chain
plvp
shown
green
ritonavir
shown
blue
lopinavir
red
darunavir
purpl
